Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy

Aim: Previous studies demonstrated l-carnitine decreasing doxorubicin-induced cardiotoxicity. Our objectives were to study carnitine levels and cardiac functions in children treated with doxorubicin and the effect of short-term l-carnitine supplements. Materials and Methods: Serial carnitine levels...

Full description

Saved in:
Bibliographic Details
Main Authors: Anant Khositseth, Suwadee Jirasakpisarn, Samart Pakakasama, Lulin Choubtuym, Duangrurdee Wattanasirichaigoon
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2011-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2011;volume=32;issue=1;spage=38;epage=42;aulast=Khositseth
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850257649862443008
author Anant Khositseth
Suwadee Jirasakpisarn
Samart Pakakasama
Lulin Choubtuym
Duangrurdee Wattanasirichaigoon
author_facet Anant Khositseth
Suwadee Jirasakpisarn
Samart Pakakasama
Lulin Choubtuym
Duangrurdee Wattanasirichaigoon
author_sort Anant Khositseth
collection DOAJ
description Aim: Previous studies demonstrated l-carnitine decreasing doxorubicin-induced cardiotoxicity. Our objectives were to study carnitine levels and cardiac functions in children treated with doxorubicin and the effect of short-term l-carnitine supplements. Materials and Methods: Serial carnitine levels and cardiac functions were obtained in children with newly diagnosed solid malignancies before doxorubicin, after cumulative doses of ≥150 mg/m 2 and ≥300 mg/m 2 , respectively. Oral l-carnitine 100 mg/kg/day for 3 days were given to the children treated with doxorubicin at cumulative doses of ≥150 mg/m 2 and ≥300 mg/m 2 . Carnitine levels and cardiac functions were also obtained in those children before and after short-term oral l-carnitine at each cumulative dose of doxorubicin. Results: Five children (3 females), median age of 9.1 years (range 1.5-13 years) with newly diagnosed solid malignancies were enrolled in the study. Free carnitine (FC) tended to decrease while acyl-carnitine (AC) increased making AC/FC ratio increased after cumulative dose of ≥150 and ≥300 mg/m 2 but the statistics was not significant. Left ventricular (LV) systolic function was not significantly changed. Interestingly, LV global function (LV myocardial performance index) was significantly increased after 150 mg/m 2 (median 0.39, 0.27-0.51) and 300 mg/m 2 (median 0.46, 0.27-0.50) when compared to baseline (median 0.28, 0.14-0.48) (P=0.05). Carnitine levels and cardiac functions were not significantly changed after oral l-carnitine supplement at cumulative dose of ≥150 mg/m 2 (n=6) and ≥300 mg/m 2 (n=9). Conclusions: Carnitine levels tended to decrease after doxorubicin treatment. LV global dysfunction was documented early after doxorubicin. However, short-term l-carnitine supplement did not improve cardiac function.
format Article
id doaj-art-482d84042d3140bb8012e6c4aaec0604
institution OA Journals
issn 0971-5851
language English
publishDate 2011-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series Indian Journal of Medical and Paediatric Oncology
spelling doaj-art-482d84042d3140bb8012e6c4aaec06042025-08-20T01:56:20ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58512011-01-01321384210.4103/0971-5851.81889Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapyAnant KhositsethSuwadee JirasakpisarnSamart PakakasamaLulin ChoubtuymDuangrurdee WattanasirichaigoonAim: Previous studies demonstrated l-carnitine decreasing doxorubicin-induced cardiotoxicity. Our objectives were to study carnitine levels and cardiac functions in children treated with doxorubicin and the effect of short-term l-carnitine supplements. Materials and Methods: Serial carnitine levels and cardiac functions were obtained in children with newly diagnosed solid malignancies before doxorubicin, after cumulative doses of ≥150 mg/m 2 and ≥300 mg/m 2 , respectively. Oral l-carnitine 100 mg/kg/day for 3 days were given to the children treated with doxorubicin at cumulative doses of ≥150 mg/m 2 and ≥300 mg/m 2 . Carnitine levels and cardiac functions were also obtained in those children before and after short-term oral l-carnitine at each cumulative dose of doxorubicin. Results: Five children (3 females), median age of 9.1 years (range 1.5-13 years) with newly diagnosed solid malignancies were enrolled in the study. Free carnitine (FC) tended to decrease while acyl-carnitine (AC) increased making AC/FC ratio increased after cumulative dose of ≥150 and ≥300 mg/m 2 but the statistics was not significant. Left ventricular (LV) systolic function was not significantly changed. Interestingly, LV global function (LV myocardial performance index) was significantly increased after 150 mg/m 2 (median 0.39, 0.27-0.51) and 300 mg/m 2 (median 0.46, 0.27-0.50) when compared to baseline (median 0.28, 0.14-0.48) (P=0.05). Carnitine levels and cardiac functions were not significantly changed after oral l-carnitine supplement at cumulative dose of ≥150 mg/m 2 (n=6) and ≥300 mg/m 2 (n=9). Conclusions: Carnitine levels tended to decrease after doxorubicin treatment. LV global dysfunction was documented early after doxorubicin. However, short-term l-carnitine supplement did not improve cardiac function.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2011;volume=32;issue=1;spage=38;epage=42;aulast=KhositsethAnthracyclinecardiac functioncardiac toxicitychildren
spellingShingle Anant Khositseth
Suwadee Jirasakpisarn
Samart Pakakasama
Lulin Choubtuym
Duangrurdee Wattanasirichaigoon
Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
Indian Journal of Medical and Paediatric Oncology
Anthracycline
cardiac function
cardiac toxicity
children
title Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
title_full Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
title_fullStr Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
title_full_unstemmed Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
title_short Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
title_sort carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
topic Anthracycline
cardiac function
cardiac toxicity
children
url http://www.ijmpo.org/article.asp?issn=0971-5851;year=2011;volume=32;issue=1;spage=38;epage=42;aulast=Khositseth
work_keys_str_mv AT anantkhositseth carnitinelevelsandcardiacfunctionsinchildrenwithsolidmalignanciesreceivingdoxorubicintherapy
AT suwadeejirasakpisarn carnitinelevelsandcardiacfunctionsinchildrenwithsolidmalignanciesreceivingdoxorubicintherapy
AT samartpakakasama carnitinelevelsandcardiacfunctionsinchildrenwithsolidmalignanciesreceivingdoxorubicintherapy
AT lulinchoubtuym carnitinelevelsandcardiacfunctionsinchildrenwithsolidmalignanciesreceivingdoxorubicintherapy
AT duangrurdeewattanasirichaigoon carnitinelevelsandcardiacfunctionsinchildrenwithsolidmalignanciesreceivingdoxorubicintherapy